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Abstract
BACKGROUND: Dual phase 99mTc-sestamibi SPECT/CT preoperative parathyroid scintigraphy (PPS) is seldom discussed 
in terms of the transport kinetics of the tracer.
Objectives: To assess the relationship between the characteristic type of tracer transport in particular PPS and histopathological 
findings in patients with secondary hyperparathyroidism (sHPT).
MATERIAL AND METHODS: The study comprised 27 patients (13 females and 14 males) with sHPT. Based on tracer accumula-
tion in early phase (EP) and delayed phase (DP), the following types of accumulation for PPS(+) lesions were identified: EP(–)/ 
/DP(+) (type I), EP(+)/DP(+) (type II), EP(+)/DP(–) (type III). EP(–)/DP(–) (type IV) lesions constituted PPS(–) group invisible 
in SPECT/CT. Overall, 69 lesions 59 PPS(+) and 10 PPS(–) were evaluated histopathologically.
RESULTS: Among SPECT/CT PPS(+), types I, II and III occurred in 9 (15%), 49 (83%), and 1 (2%) lesions, respectively. The 
frequency of histopathological diagnosis of normal and abnormal (APG — adenoma or hyperplasia) parathyroid gland, as well 
as non-parathyroid (thyroid, lymph nodes, or fat) lesions differed significantly between type I, II, and III lesions (p = 0.036). 
APG histopathological diagnosis was significantly more frequent in lesions with type II uptake than in lesions with type I uptake 
(76% vs. 33%, p = 0.0197). Type II lesions had significantly higher odds for histopathological diagnosis of APG or NPG than 
type IV, PPS(–) lesions [odds ratio = 13.1 (95% CI: 2.75 to 63.27)].
CONCLUSIONS: For SHP patients evaluated with SPECT/CT PPS accumulation type I is a weak premise for surgeon to find 
parathyroid pathology. Only persistent 99mTc-sestamibi accumulation in both phases - equivocal with accumulation type II 
— effectively differentiates parathyroid and non-parathyroid lesions as well as indicates with high probability the presence of 
adenoma or hyperplasia. Type III consistent with washout pattern is rare in sHPT. 
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Secondary hyperparathyroidism (sHPT) is usually caused 
by chronic kidney disease in response to hypocalcaemia, which 
leads to diffused or nodular hyperplasia of the parathyroid glands. 
Even after successful renal replacement therapy, this condition can 
be difficult to control using conservative treatments, and hence 
require parathyroid surgery [1–3]. If surgical intervention is not 
performed in the optimal time, some patients can develop auto-
nomic adenoma with a constant elevation of PTH [4, 5]. Among 
various preoperative imaging techniques, single-photon emission 
computed tomography (SPECT) is an accurate method used for 
the localization of abnormal parathyroid gland method. Recently, 
new hybrid imaging using SPECT in combination with computed 
tomography (CT) has improved precision in the morphological and 
metabolic assessment of focal lesions [6].
99mTc-methoxyisobutylisonitrile (99mTc-sestamibi) SPECT/CT 
preoperative parathyroid scintigraphy (PPS) can be performed 
as dual-phase single-tracer scintigraphy (washout method). There 
are two patterns of washout from the parathyroid glands: delayed 
(parathyroid gland retention of radiopharmaceutical on delayed 
images, usually accompanied by normal washout from the thyroid) 
and early (minimal or no retention of the radiotracer in the para-
thyroid gland on delayed-phase images). It was shown that the 
metabolic activity of the thyroid tissue diminishes with time while 
in the parathyroid tissue is more protracted; hence, early phase 
(EP) in SPECT/CT refers to the thyroid washout and the delayed 
phase (DP) to the parathyroid washout [7, 8]. Accumulation of 
99mTc-sestamibi may be visible either in one phase only or both 
phases, thus leading to three different types of trace patterns [9]. 
The purpose of this study was to evaluate the relationship be-
tween the transport kinetics of 99mTc-sestamibi in SPECT/CT PPS 
and histopathological findings in patients with sHPT who underwent 
parathyroid surgery.
Material and methods
We included 78 patients with sHPT (30 females, 48 males; 
mean age of 49.9 years, range: 22–86 years). Patients were exam-
ined with planar and SPECT/CT PPS (GE INFINIA Hawkeye 4 with 
a low-energy high-resolution collimator and 2.0 zoom) following in-
travenous administration of 99m Tc-sestamibi 762 ± 60.7 MBq (range: 
600–850) with washout technique (dual-phase, single-tracer), in 
accordance with EANM guidelines [8]. The SPECT/CT study in EP 
was started following thorax planar acquisition (but not later than 
20 min after administration of the tracer), and DP was performed 
127 ± 28 min after tracer administration. 
Pathological lesions on SPECT/CT were observed in 73 
patients, and negative results in 5 patients. Among them, 27 
patients (14 males and 13 females; mean age 46.3 years, range: 
22–77 years) with abnormal lesions seen in the SPECT/CT study 
and inadequately controlled sHPT despite standard medical therapy 
were qualified for parathyroid surgery. PTH plasma concentra-
tion exceeding 600 pg/ml was an eligibility criterion for surgery. 
Among 26 patients with renal sHPT, 25 received kidney replace-
ment therapy. Coeliac disease was diagnosed in one patient with 
sHPT. Two patients required second parathyroid surgery 4 and 
19 months after the first operation.
Sonography of the neck was performed parallel to the scintigra-
phy at the same department in all cases, but results of the study had 
only a supportive function in terms of the results of the study [10]. 
Measurements to estimate accurately their volume were performed 
in 18.8% of all histopathologically assessed lesions. 
We defined a positive result in early and delayed SPECT/CT 
as the presence of identifiable focus of increased 99mTc-sestamibi 
accumulation in the vicinity of the thyroid gland, or localized outside 
of the thyroid gland in the neck or mediastinum. 
The SPECT/CT method of PPS allowed positioning the anatomic 
localization of metabolically active lesions in three-dimensional 
projections. Separate sets of fusion images were delivered to 
the surgeon to facilitate surgical treatment planning. Removed 
tissue specimen were secured and, after recording their location, 
transferred to the pathology lab for histopathological examination.
The specific histopathological diagnoses were correlated 
with the type of 99mTc-sestamibi uptake in the lesions, serum PTH, 
phosphate, total, and ionized calcium.
In surgical centres, PTH measurements were performed post-
operatively. Direct, postoperative PTH assays were performed in 
22 patients.
SPECT/CT results were considered true positive (TP) if a lesion 
was SPECT/CT PPS(+) and diagnosed as an abnormal parathyroid 
gland (APG — parathyroid adenoma and parathyroid hyperplasia) 
or normal parathyroid gland (NPG) on histopathological diagno-
sis; false positive (FP) if a lesion was SPECT/CT PPS(+) but not 
parathyroid lesions (lymph nodes, fat, thyroid tissue) (Non-PL) on 
histopathological diagnosis, true negative (TN) was characterized 
as SPECT/CT PPS(–) and confirmed as not of  parathyroid origin on 
histopathological diagnosis and false negative (FN) as SPECT/CT 
PPS(–) and diagnosed as APG or NPG histopathologically. 
The study was approved by the Pomeranian Medical University 
Ethics Committee and all patients gave their written consent. 
Statistical analysis
Normality of distribution for serum PTH concentration was ex-
amined by the Kolmogorov-Smirnov test. Since the PTH distribu-
tion was significantly different from normal, the Kruskal-Wallis test 
was used to compare PTH between independent groups. Fish-
er’s exact test was used for assessing the significance of the 
association between types of accumulation and histopathological 
diagnosis. Statistical analysis was performed with IBM SPSS 23. 
The threshold for statistical significance was p < 0.05. 
Results
In 27 patients 65 lesions SPECT/CT PPS(+) on SPECT/CT 
were detected, but 6 of them were not found during surgery. During 
operations on 7 patients from this group, the surgeon additionally 
removed 10 lesions not indicated on SPECT/CT, and then we called 
it SPECT/CT PPS(–). As a result, 69 lesions were validated on the 
histopathological diagnosis. In total, 5 patients had a single lesion, 
9 patients had 2 lesions, 7 patients had 3 lesions, 5 patients had 
4 lesions, and 1 patient had 5 lesions. 
The group of 59 lesions SPECT/CT PPS(+) with an additional 
10 lesions SPECT/CT PPS(-) had the following histopathologi-
cal diagnoses: 28 + 0 (40.6%) — parathyroid adenoma, 12 + 2 
(20.3%) — parathyroid hyperplasia, 10 + 2 (17.4%) — NPG, 3 + 1 
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(5.8%) — lymph node and 6 + 4 (14.5%) — normal thyroid gland 
tissue, 0 + 1 (1.4%) — fatty tissue. 
Biochemistry data obtained before surgery are presented in 
Table 1. 
To analyze the association between PTH and the histopatho-
logical diagnosis we compared PTH concentrations between 
three groups of patients: 1) 16 patients with parathyroid adenoma 
Table 1. Baseline biochemical analyses before surgery
Serum concentration 
(reference range)
Mean (± SD) Median (Q25–Q75)
Ionized calcium  
(1.05–1.35 mmol/L)
1.49 ± 0.47 1.35 (1.15–1.9)
Total calcium  
(2.1–2.6 mmol/L)
2.29 ± 0.23 2.32 (2.08–2.51)
Phosphorus  
(0.87–1.45 mmol/L)
1.90 ± 0.63 1.76 (1.33–2.54)
PTH (16–65 pg/mL) 1701.92 ± 763.40 1600.00 (1272–2500)
Creatinine  
(0.7–1.5 mg/dL)
5.71 ± 2.18 5.92 (4.90–6.93)
Urea (15–40 mg/dL) 74.18 ± 37.69 71 (51–91.15)
Q25–Q75 — interquartile range; SD — standard deviation
Figure 1. Three types of 99mTc-sestamibi SPECT/CT uptake in fusion coronal cross-sections; A. Type I — the tracer is visible in the delayed 
phase for right upper parathyroid gland. HP proved as adenoma (patient ZG, 56 y.o.); B. Type II — tracer is visible in both phases for right lower 
parathyroid gland. HP proved as adenoma (patient LM, 57 y.o.); C. Type III — the tracer is visible in the early phase for right upper parathyroid 
gland HP proved as NPT (patient LM, 57 y.o.). White arrows show lesions with or without uptake in corresponding phases of SPECT/CT PPS
in histopathological diagnosis for at least one location, 2) 7 pa-
tients with parathyroid hyperplasia in histopathological diagno-
sis for at least one location, and 3) 4 patients with NPG or other 
histopathological diagnosis but without parathyroid adenoma or 
parathyroid hyperplasia at any location. There was no single patient 
with both parathyroid adenoma and parathyroid hyperplasia in dif-
ferent locations. There was no significant difference between those 
groups as regards PTH concentration (p = 0.18, Kruskal-Wallis test). 
In a positive SPECT/CT PPS (PPS+), we identified three types of 
the uptake accumulation: Type I with the absence of  accumulation 
in the early phase and retention in the delayed phase (EP-/DP+), 
Type 2 with accumulation in both phases (EP+/DP+), Type III with 
the uptake observed only in the EP(EP+/DP–). 
Additionally, we identified Type IV, in which the lesions were not 
detected by SPECT/CT but were found and removed during surgery 
(Type IV EP-/DP–). The parathyroid lesion was defined if it was lo-
calized dorsally to the thyroid lobe and the uptake in SPECT/CT 
was classified either as type I or type II [11]. In the type III uptake, 
the localization criterion was decisive. None of the patients had 
ectopic localization of lesions.
In the lesion-based analysis, there were 9 (15.3%), 49 (83%) 
and 1 (1.7%) lesions SPECT/CT PPS(+) characterized as types I, 
II and III, respectively (Fig 1).
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Among 69 removed lesions 50 were acknowledged as TP, 9 
lesions as FP, 4 lesions as FN, 6 lesions as TN. In type I the rate 
of TP achieved 5(55%) lesions, in type II — 44 (90%), in type III 
— 1(100%) lesion, whereas in type IV SPECT/CT PPS(–) achieved 
4 (40%) lesions (Tab. 2). 
In 13 (18.8%) lesions removed by the surgeon in 3 hyper-
plasia and 7 adenomas the average volume was 0.38 mL and 
0.41 mL, respectively. All those lesions presented as type II on 
PPS SPECT/CT study.
The statistical analysis for the whole PPS(+) group showed 
significant differences between accumulation types I, II or III and 
results of histopathological examination (p = 0.036). A comparison 
between types I and II of 99mTc-sestamibi accumulation showed 
significant (p = 0.025) differences in histopathological diagno-
sis (Tab. 2).
The association of detailed histopathological diagnosis with 
SPECT/CT uptake type is shown in Table 3.
There were no significant differences between lesions with type 
I and type II uptake as regards proportions of parathyroid adeno-
mas (33% vs. 51%, p = 0.473) and parathyroid hyperplasia (0% vs. 
24%, p = 0.181) in relation to histopathological diagnosis. However, 
when parathyroid adenomas and parathyroid hyperplasia were 
combined as APG, this diagnosis was significantly more frequent in 
lesions with type II uptake than in lesions with type I uptake (76% vs. 
33%, p = 0.0197). The frequency of APG was significantly different 
between types II and IV (76% vs. 20%, respectively, p = 0.0016), 
but not between types I and IV (33% vs. 20%. p = 0.628).
Combined lesions with positive uptake (types I, II and III) had 
significantly higher odds for combined histopathological diagno-
sis of APG and NPG than lesions with negative uptake (type IV) 
[OR = 8.33 (95% CI: 1.95–35.54), p = 0.004]. Type II lesions had 
the highest odds ratio for APG or NPG when compared to type 
IV lesions [OR = 13.1 (95% CI: 2.75 to 63.27), p = 0.001], while 
type I lesions did not have significantly higher odds for APG or 
NPG than type IV lesions [OR = 1.88 (95% CI: 0.30  to 11.63), 
p = 0.499]. 
The SPECT/CT 99mTc-sestamibi PPS quality parameters for 
detecting APG or NPG on the basis of positive (type I-III) uptake 
were sensitivity 92.6%, specificity 40.0%, accuracy 81.2%, posi-
tive predictive value 84.7% and negative predictive value 60.0% 
was achieved. 
Discussion
Even if some articles are focused on parathyroid scanning with 
99mTc-sestamibi in sHPT, there is limited data about its correlation 
with histopathology [12, 13]. SPECT/CT PPS has lately been re-
garded as the method of choice [6, 14, 15]. The main purpose of the 
study was to find pathological lesions, and the next one was to apply 
the best procedure to find them effectively. The method of washout 
analysis was rarely correlated with particular types of uptake and 
the final results of the study [16]. However, Carpertier, in one of 
the first articles about the utility of 99mTc-sestamibi in preoperative 
diagnosis of hyperparathyroidism, wrote about the EP and DP 
phases of the study [17]. Yang compared EP and DP results and 
pointed out the importance of dual-phase analysis methodology 
on final results [9]. 
In our study special attention was paid to the presence or ab-
sence of tracer accumulation in particular phases of the study. In 
this context, our approach is quite innovative. In the current paper, 
lesions were assessed according to their visibility in both phases of 
PPS and compared with histopathology.
To our knowledge, this is the first comparison performed be-
tween the transport kinetics of 99mTc-sestamibi and histopathological 
results in particular lesions for sHPT patients. 
In our material type, I turned out not to be diagnostic for dis-
crimination of whether the lesion is or is not of parathyroid origin. 
This is depicted by significantly lower odds for histopathological 
diagnosis of APG or NPG for type I in comparison to type II.
Table 3. Association of SPECT/CT 99mTc-sestamibi results and uptake types with histopathological diagnosis in sHPT









Positive APG Parathyroid adenoma 3a 25a – - 28
Parathyroid hyperplasia – 12a – 2c 14
NPG Normal parathyroid gland 2a 7a 1a 2c 12
Negative Non–PL Thyroid tissue 2b 4b – 4d 10
Lymph node 2b 1b – 1d 4
Fatty tissue – – – 1d 1
Total 9 49 1 10 69
aTP — true positive; bFP — false positive; cFN — false negative; dTN — true negative; APG — abnormal parathyroid gland, NPG — normal parathyroid gland; SPECT/CT PPS(+) — lesions 
visible in SPECT/CT preoperative parathyroid scintigraphy; SPECT/CT PPS(-) — lesions not visible in SPECT/CT preoperative parathyroid scintigraphy; EP — early phase; DP — delayed phase
Table 2. Association of SPECT/CT 99mTc-sestamibi results and type of 
uptake with parathyroid or non-parathyroid lesions in histopathological 
evaluation





TYPE I (EP–/DP+)a 5 4
TYPE II (EP+/DP+)a 44 5 0.036*
TYPE III (EP+/DP–)a 1 0
TYPE IV (EP–/DP–)b 4 6 N/A
Total 54 15 69
*Fisher exact test for types I–III; EP — early phase; DP — delayed phase; N/A — not 
applicable ; aSPECT/CT PPS(+) for types I–III lesions visible in SPECT/CT preoperative 
parathyroid scintigraphy; bSPECT/CT PPS(–) for type IV lesions not visible in SPECT/CT 
preoperative parathyroid scintigraphy. 
}
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Type II uptake was predominant in the examined group. 
As a practical remark, it might be valuable to point out in the report of 
the PPS study the type 99mTc-sestamibi uptake. Such lesions would 
have higher odds of being APG or NPG. The explanation might be 
the greater number of mitochondrias, and the ability of parathyroid 
cells to persistently capture 99mTc-sestamibi in comparison with 
Non-PL. 
For parathyroid adenomas and parathyroid hyperplasias, type 
II accumulation was observed in 90% and 86%, respectively, while 
type I accumulation was noted in 10% of adenoma le sions. The 
examined group consisted of patients with relatively high ratios of 
parathyroid ade noma to hyperplasia (ratio 2:1) and was different 
compared with data obtained by Yuan [6]. The explanation for 
this fact might be the relatively long waiting time for kidney trans-
plantation in our country [18]. This fact in patients with sHPT refrac-
tory to medical treatment promoted the evolution of parathyroid 
gland hyperplasia into adenoma [2, 19, 20]. This happens because 
of alternation in parathyroid tissue growth pattern from polyclonal 
to monoclonal or multiclonal proliferation [21]. 
The presence of increased uptake of 99mTc-sestamibi only in DP 
or increased activity of a tracer in both phases (EP and DP) are the 
main principles of the washout protocol [22, 23]. The 99mTc-sestamibi 
clearance from the lesion is a well-known phenomenon in the case 
of pHPT patients, and it is assessed as from 17% to 40% of all 
cases of parathyroid scintigraphy [24–27]. In our material type III 
uptake was presented only in one case, perhaps be cause there 
is a differ ent aetiology of primary hyperparathyroidsim (pHPT) and 
sHP [6, 28]. The lesion with this kind of uptake misleads nuclear 
medicine practitioners suggesting the thyroid origin of the lesion. 
Quick clearance typical of thy roid tissue is a cause of false-negative 
findings, and researchers over come it by per forming thyroid 
scans with 123I after the 99mTc-sestamibi scan [14]. On the other 
hand, it leads to a disadvantage in image interpretation because 
of the “shine through” phenomenon [29]. In our opinion, it is not 
necessary when the SPECT- CT technique is applied. Localization 
of the lesion behind the thyroid gland indicates its parathyroid rather 
than thyroid origin regardless of the type of transport kinetics type 
[14, 30]. Furthermore, the better technical possibili ties related to 
the use of hybrid techniques and structural imaging have resulted 
in better sensitivity compared to previous planar or SPECT modal-
ity, even if in sHPT lesions are multiple and smaller [6, 14, 31, 32].
Surgeons removed 12 (17.4%) lesions of NPT because they 
were visible in parathyroid scintigraphy. These findings are simi-
lar to the 15.8% noted in the publication by Yuan [6]. High PTH 
plasma concentration (greater than in pHPT) might influence 
and stimulate to some extend NPG [7, 33]. However, Bolasco 
found one case of sHPT treated with cinacalcet where despite 
the lowering PTH plasma level 99mTc-sestamibi uptake in APG 
was unchanged [34]. 
SPECT/CT PPS helped in choosing lesions to be removed. 
Nowadays, it is believed that if four glands exploration parathyroid 
surgery is necessary, surgeons should remove three glands and 
a half of the fourth with the most normal appearance, leaving the re-
maining half in situ [6]. For the 27 patients, the estimated number of 
removed parathyroid glands should have been minimum 81 glands, 
but 69 glands were removed. So, SPECT/CT PPS re sults helped to 
limit the number of resected glands, shortened the duration time of 
the surgery, and di minished the failure rate. However, it is possible 
that in the operating theatre lesions suspected of pathology by the 
surgeon would be removed during the exploration, even if there 
is no indi cation in preoperative diagnosis. It is important to admit 
this in terms of the limitation of our study. The study was conducted 
in just one university centre. The surgeons’ skills, preopera tive as-
sessment, and the experience of nuclear medicine specialists will 
affect the outcome of the study. 
A sensitivity of 92.6% and accuracy of 81.2% is comparable with 
the literature data [2, 30]. A specificity of 40% is much lower than 
that achieved by other authors [2, 6, 9, 30, 35]. This could have 
been affected by including Type IV lesions in the calculation. Type 
IV consisted of lesions removed by the surgeon despite the lack of 
accumulation of the tracer in scintigraphy. It is worth mentioning in 
this context that our study provides additional quality parameters not 
available in other papers as the odds ratio for successful surgery in 
particular transport kinetics types in patients with sHPT. 
In the current study as well as in the literature there was no 
statistical relation between histopathological diagnosis and PTH 
level. The explanation may be that pharmacological treatment in 
sHPT patients influences their PTH level [36]. In our study, the rec-
ommendation for surgery was PTH level of more than 600 pg/mL. 
The same criteria were applied by Souberbielle and Rosato [33, 37]. 
Separation into three groups of tracer uptake was used in previ-
ous studies with 99mTc-ses tamibi performed for different indications. 
For example, the kinetics of the tracer was used as a predictor of 
tumour response to chemotherapy treatment. It combined imagin-
ing findings with prognostic value in patients with breast cancer, 
lymphoma, and small and non-small cell lung cancer [38]. Different 
kinetics of 99mTc-sestamibi depicted a multidrug resistance pheno-
type prior to preoperative diagnosis or any treatment. The above 
idea inspired us to perform the comparison between 99mTc-sestamibi 
uptake in SPECT/CT PPS and different histopathologi cal diagno-
sis in sHPT. 
The genetic factors influencing parathyroid uptake in 
patients with hyperparathyroidism were postulated in some 
publications [39–41]. But there is still a limited number of genet-
ics studies investigating the background of the transport kinetics of 
99mTc-sestamibi in patients with sHPT. Also, different mathematical 
models of transport kinetics have been created but there is a lack of 
clinical studies [42]. The authors of the presented study performed 
genetic studies in patients with hyperparathyroidism and proved the 
significant negative correlation of mRNA expression for the ABCC1 
gene with maximal 99mTc-sestamibi uptake values in patients with 
hyperparathyroidism [43, 44]. There is a need for further investiga-
tion in this field.
Conclusions
For sHPT patients evaluated with SPECT/CT PPS accumula-
tion type, I is a weak premise for a surgeon to find parathyroid 
pathology. Only persistent 99mTc-sestamibi accumulation in both 
phases — equivocal with accumulation type II — effectively dif-
ferentiates parathyroid and non-parathyroid lesions as well as indi-
cates with high probability the presence of adenoma or hyperplasia. 
Type III, consistent with washout pattern, is rare in sHPT.
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